Differentiated Thyroid Cancer GUIDELINES Pocket Guide

Differentiated Cancer

Approved By

American Thyroid Association

Digital Subscription $4.99 Add to Cart
Print $13.95 Add to Cart
Free Sample

The digital subscription version of the Differentiated Thyroid Cancer GUIDELINES Pocket Guide contains all the same great information found in the physical pocket guide, and can be accessed on mobile devices and online:

  • Price: $4.99 per year
    • Subscribe to additional guideline titles for discounted rates
  • Includes automatic updates during the term of your subscription
  • CPT® and ICD10 codes can be added to certain guidelines for an additional fee
  • Supported platforms
    • iPhone and iPad
    • Android phones and tablets
    • Online (internet connection required)
  • Content on the Guideline Central mobile app accessible without an internet connection
    • Access to additional guideline summaries, clinical calculators, and more

For mobile access, download the free app from the App Store or Google Play and use the same email address and password as the website to login.

For individual use only; contact us for group and site licenses.

The Differentiated Thyroid Cancer GUIDELINES Pocket Guide is based on the latest guidelines of the American Thyroid Association and was developed with their collaboration. This practical quick-reference tool contains  key points,  101 detailed, evidence-graded recommendations for managing recurrent or persistent differentiated thyroid cancer, four management algorithms, and tables dealing with disease classification, treatment response, risk.

  • Spiral Bound
  • 32 Pages
  • 80# Diamond Silk Cover with Satin Aqueous Coating
  • 4.25″ x 7.25″
  • Key Points 
  • Graded Treatment Recommendations 
  • Tables 
    • Ultrasound Features of Lymph Nodes Predictive of Malignant Involvement 
    • AJCC 7th edition/TNM Classification System for Differentiated Thyroid Carcinoma
    • Pre-operative Factors Which May Be Associated With Laryngeal Nerve Dysfunction
    • Best Response to Therapy
    • Clinical Implications of Response To Therapy Re-Classification in Differentiated Thyroid Cancer Patients Treated With Total Thyroidectomy and RAI Remnant Ablation
    •  Characteristics According to the ATA Risk Stratification System and AJCC/TNM Staging System That May Affect Post-operative RAI Decision-Making
    • Response to Therapy Re-Classification
    • TSH Targets for Long-term Thyroid Hormone Therapy
    •  Factors to Review When Considering Kinase Inhibitor Therapy
    • Potential Toxicities and Recommended Screening or Surveillance Monitoring Approaches in Patients Started on Kinase Inhibitor Therapy
  • Algorithms 

The ATA is the leading organization devoted to thyroid biology and to the prevention and treatment of thyroid disease through excellence in research, clinical care, education, and public health. To learn more, visit - http://www.thyroid.org/professionals/ata-professional-guidelines/

  • Guideline Pricing

  • Single Title
    $4.99 / year
  • Any 5 Titles
    $23.99 / year
  • Any 10 Titles
    $41.99 / year
  • Any 35 Titles
    $74.99 / year
  • All Available Titles
    $169.99 / year

To get started, log in or create your free account Create Account